South Korea has rapidly emerged as a powerhouse in life sciences. With a pharmaceutical market valued at USD 21.8 billion in 2024, it is now the 3rd largest pharmaceutical market in Asia and home to several globally competitive pharmaceutical and biotech companies.
As Korean manufacturers expand their capabilities, the industry is accelerating into new modalities and advanced therapies, supported by a strong track record of international licensing deals and cross‑border research collaborations.
South Korea is also one of the world’s most digitally advanced societies, offering a unique environment for innovation in digital health and AI‑driven technologies. With the government prioritizing AI adoption in pharmaceuticals and healthcare, major Korean pharma companies have already announced strategies to integrate AI into R&D pipelines and diversify their business portfolios.
As global demand grows for innovative research partners and digital health solutions, Korean companies are increasingly open to collaborating with international startups and organizations to drive the next wave of healthcare innovation.